GlobeNewswire by notified

Philips shareholders approve all proposals at the AGM 2024

Share

May 7, 2024

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that its shareholders approved all proposals at the Annual General Meeting of Shareholders (AGM) 2024, including:

  • The re-appointment of Chairman Feike Sijbesma and Peter Löscher as members of the Supervisory Board.
  • The appointment of Benoît Ribadeau-Dumas as member of the Supervisory Board.
  • The appointment of Charlotte Hanneman as member of the Board of Management, with effect from October 1, 2024.
  • The discharge of the members of the Board of Management and members of the Supervisory Board.
  • A full overview of the resolutions taken at the AGM 2024 can be found below.


Feike Sijbesma, Chairman of Philips’ Supervisory Board, said: “I am very pleased with the re-appointment of Peter and the appointment of Benoît, who has extensive experience with large and global industrial companies. With our highly knowledgeable and experienced members, the composition of our Supervisory Board is very strong and well positioned to fulfill our vital duty of advising, challenging, and supporting Management in executing Philips’ strategy, and it is an honor to serve a second term leading this Board.

I would also like to welcome Charlotte to Philips. She will join Philips’ Board of Management on October 1, and fulfill the role of Chief Financial Officer. Her strong MedTech knowledge and extensive finance experience, coupled with her energy and passion for the healthcare industry, make her an ideal fit for the role. Charlotte will work with Abhijit, Philips’ current Chief Financial Officer, until October, ensuring a smooth transition. I would also like to thank Abhijit in advance for his tremendous contribution to Philips over the last 38 years, and more particularly during his nine years as Chief Financial Officer.”

Roy Jakobs, CEO of Royal Philips said: “I want to congratulate our Chairman Feike with his re-appointment. Together with Peter and Benoît, as well as the other Supervisory Board members, they represent the best in the industry to provide oversight and valuable insights to Management in executing Philips’ 2023-2025 plan to create value with sustainable impact for all stakeholders. We look forward to a continued strong and successful collaboration, as we aim to improve the health and well-being of people through meaningful innovation.”

All resolutions taken at the AGM 2024:

Agenda itemResolution
2Annual Report 2023
  • Adoption of the financial statements 2023
  • Adoption of a dividend of EUR 0.85 per common share, in common shares, against retained earnings
  • Positive advisory vote on the approval of the Remuneration Report 2023
  • Discharge of the members of the Board of Management
  • Discharge of the members of the Supervisory Board
3Composition of the Board of Management
  • Appointment of Ms Hanneman as member of the Board of Management with effect from October 1, 2024
4Composition of the Supervisory Board        
  • Re-appointment of Mr Sijbesma as member of the Supervisory Board with effect from May 7, 2024
  • Re-appointment Mr Löscher as member of the Supervisory Board with effect from May 7, 2024
  • Appointment of Mr Ribadeau-Dumas as member of the Supervisory Board with effect from May 7, 2024
5Remuneration of the Board of Management and the Supervisory Board
  • Adoption of Remuneration Policy for the Board of Management
  • Adoption of Remuneration Policy for the Supervisory Board
6Authorization of the Board of Management to issue shares or grant rights to acquire shares and restrict or exclude pre-emption rights
7Authorization of the Board of Management to acquire shares in the company
8Cancellation of shares

Further details about the dividend can be found via this link, and additional information on the composition of the Board of Management, the Executive Committee and the Supervisory Board can be found here. Philips’ 2023 financial statements are included in its Annual Report 2023 that was published on February 20, 2024.

For more information about Philips’ AGM 2024, please click on this link.

For further information, please contact:

Elco van Groningen
Philips External Relations
Tel.: +31 6 8103 9584
E-mail: elco.van.groningen@philips.com

Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,100 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea7 awarded a contract for the Belinda field in the UK North Sea25.5.2024 14:01:09 CEST | Press release

Luxembourg – 25 May 2024 - Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base and for controls at the Evelyn valve skid. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio25.5.2024 12:15:00 CEST | Press release

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor,demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atr

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo25.5.2024 12:00:00 CEST | Press release

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3Fabhalta showed a favorable safety profile with no new safety signals1C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9 Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to support

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye